A carregar...
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment...
Na minha lista:
| Publicado no: | Korean J Intern Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Korean Association of Internal Medicine
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4773721/ https://ncbi.nlm.nih.gov/pubmed/26874514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2015.024 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|